Arcus Biosciences, Inc. (RCUS)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Arcus Biosciences, Inc. reported revenue of $33.00M, down 35.3% from the prior year. The company ran a net loss, with a net margin of -1069.7%.
Key ratios (FY2025)
-1169.7%
Operating margin
-1069.7%
Net margin
-55.9%
Return on equity
-35.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.00M | $51.00M | $37.00M | $38.00M | $383.00M | $78.00M | $15.00M | $8.35M | — | — |
| Operating Income | -$386.00M | -$330.00M | -$340.00M | -$280.00M | $54.00M | -$124.00M | -$88.71M | -$54.86M | -$53.44M | -$18.18M |
| Net Income | -$353.00M | -$283.00M | -$307.00M | -$267.00M | $53.00M | -$123.00M | -$84.71M | -$49.59M | -$53.08M | -$17.97M |
| EPS (Diluted) | $-3.29 | $-3.14 | $-4.15 | $-3.71 | $0.71 | $-2.24 | $-1.93 | — | — | — |
| Total Assets | $1.14B | $1.15B | $1.09B | $1.34B | $1.59B | $772.29M | $203.11M | $274.93M | $190.49M | — |
| Total Liabilities | — | — | — | — | $750.45M | $269.99M | $39.27M | $39.98M | $36.62M | — |
| Shareholders' Equity | $631.00M | $485.00M | $462.00M | $657.00M | $842.00M | $502.00M | $164.00M | $234.94M | -$72.33M | -$19.99M |
| Cash & Equivalents | $222.00M | $150.00M | $127.00M | $206.00M | $148.00M | $173.41M | $57.94M | $71.06M | $98.43M | $65.16M |
| Operating Cash Flow | -$482.00M | -$170.00M | -$306.00M | $438.00M | -$256.00M | $111.00M | -$73.46M | -$43.00M | -$25.06M | -$12.94M |
| Capital Expenditures | $2.00M | $6.00M | $24.00M | $6.00M | $26.00M | $3.00M | $1.93M | $3.74M | $5.51M | $4.10M |
| Shares Outstanding | 125.30M | 92.20M | 75.50M | 72.90M | 70.80M | 65.11M | 45.93M | 44.54M | 4.09M | — |